Abstract 235P
Background
Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor recently approved for treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of prior platinum-containing chemotherapy. Since FGFR genomic alterations have become a cornerstone in UC, we aimed to assess the prognostic role of the IHC expression of FGFR2 and FGFR3 in UC patients.
Methods
This retrospective study included cases of invasive urothelial carcinoma either pure or with squamous differentiation. All biopsies were stained for FGFR2 and FGFR3 antibodies. Complete clinical and survival data were collected and analyzed.
Results
This study included sixty patients with urothelial carcinoma. FGFR2 positivity is significantly associated with high grade and advanced stage (P= 0.044, and 0.048 respectively). Also, median FGFR2 IRS was higher in high grade cases (P= 0.027). Moreover, cases presented with PNI showed a higher median percentage of FGFR2 (P= 0.023). Furthermore, There is significant indirect linear correlation between FGFR3 percent of expression and number of positive lymph nodes (r= -0.265, P=0.041). After median follow up duration of 39 months, forty-four patient had available data for survival analysis, the mean OS and PFS were 47.4 (95% CI= 39.4-55.5) and 47.3 (95%CI= 38.7-56) months, respectively. The univariate analysis for OS revealed that presence of anemia at presentation, advanced TNM stage, and presence of distant metastasis are associated with shorter OS time ( P = 0.011, 0.007, and 0.002, respectively. Regarding PFS, the univariate analysis showed the presence of hydronephrosis at presentation is associated with shorter PFS ( P =0.029). Moreover, as with OS, presence of anemia at presentation, advanced TNM stage, and distant metastasis negatively affect PFS ( P = 0.035, 0.014, and 0.004, respectively. Regarding FGFR2 & 3 immunostaining no significant effect on neither OS nor PFS.
Conclusions
High FGFR2 expression may be associated with poor prognostic parameters, while high FGFR3 expression may be associated with good prognostic parameters.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufeya University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract